Advanced Bitcoin Technologies AG Q1 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

  • Adjusted EPS: $0.98, exceeded analyst expectations.
  • Updated Full-Year Guidance:
    • Adjusted EPS: $4.55–$4.70, raised from January guidance.
    • Organic Sales Growth (excluding COVID testing): 8.5%–10% (previously unspecified midpoint).
  • Q1 Organic Sales Growth: 4.7% overall; 10.8% excluding COVID testing.
  • Segment Highlights:
    • Nutrition: Sales up 8%, driven by U.S. pediatric share gains and international performance. Launch of PROTALITY (weight loss nutrition shake).
    • Established Pharmaceuticals (EPD): Sales up 14%, marking fourth double-digit growth quarter in last five. Margin profile improved 350bps since 2019.
    • Diagnostics: Sales up 5% excluding COVID testing. FDA approved 15-minute point-of-care concussion test using i-STAT Alinity system.
    • Medical Devices: Sales up 14%, driven by strong performance across all categories:
      • Diabetes Care (Libre): Sales of $1.5B, up 23%. Progress in basal insulin reimbursement in Germany. Global expansion underway.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Robert Ford - Chairman and Chief Executive Officer: Phil Boudreau - Senior Vice President, Finance and Chief Financial Officer: Bob Funck - Executive Vice President, Finance: Operator: Good morning, and thank you for standing by. Welcome to Abbott's First Quarter 2024 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of this call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participants’ questions asked during the question-and-answer session, the entire call, including the question-and-answer session is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Mike Comilla: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; Bob Funck, Executive Vice President, Finance; and Phil Boudreau, Senior Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2024. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materiall

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional